Tiopronin

Basic Information

Item Value
DrugBank ID DB06823
Evidence Level L5 (Computational Prediction)
Number of Predicted Indications 53

Predicted Indications (TxGNN)

The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.

# Indication Source
1 renal tubular acidosis KG + DL
2 adult polyglucosan body disease KG + DL
3 glycogen storage disease due to glycogen branching enzyme deficiency, fatal perinatal neuromuscular form KG + DL
4 glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form KG + DL
5 tricarboxylic acid cycle disorder KG + DL
6 disease of transporter activity KG + DL
7 pyruvate metabolism disorder KG + DL
8 inborn disorder of fatty acid oxidation and ketone body metabolism KG + DL
9 glycogen storage disease due to glycogen branching enzyme deficiency, progressive hepatic form KG + DL
10 glycogen storage disease due to glycogen branching enzyme deficiency, childhood combined hepatic and myopathic form KG + DL
11 glycogen storage disease due to glycogen branching enzyme deficiency, childhood neuromuscular form KG + DL
12 glycogen storage disease due to glycogen branching enzyme deficiency, non progressive hepatic form KG + DL
13 glycogen storage disease due to glycogen branching enzyme deficiency, adult neuromuscular form KG + DL
14 glycogen storage disease due to glucose-6-phosphatase deficiency KG + DL
15 granulomatous disease, chronic, X-linked KG + DL
16 glycogen storage disease due to hepatic glycogen synthase deficiency KG + DL
17 mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies KG + DL
18 anemia, nonspherocytic hemolytic, due to G6PD deficiency KG + DL
19 monosomy X KG + DL
20 classic galactosemia KG + DL
21 galactokinase deficiency KG + DL
22 primitive portal vein thrombosis KG + DL
23 hepatoportal sclerosis KG + DL
24 idiopathic copper-associated cirrhosis KG + DL
25 hepatopulmonary syndrome KG + DL
26 early-onset familial noncirrhotic portal hypertension KG + DL
27 hepatic porphyria KG + DL
28 oculocerebral hypopigmentation syndrome, Cross type KG + DL
29 galactose epimerase deficiency KG + DL
30 paraplegia KG + DL
31 hereditary North American Indian childhood cirrhosis KG + DL
32 Griscelli syndrome KG + DL
33 X-linked recessive ocular albinism KG + DL
34 Hermansky-Pudlak syndrome without pulmonary fibrosis KG + DL
35 albinism KG + DL
36 Hermansky-Pudlak syndrome with pulmonary fibrosis KG + DL
37 ocular albinism with sensorineural deafness KG + DL
38 ocular albinism (disease) KG + DL
39 ermine phenotype KG + DL
40 piebaldism KG + DL
41 inborn disorder of bilirubin metabolism KG + DL
42 minimal pigment oculocutaneous albinism type 1 KG + DL
43 temperature-sensitive oculocutaneous albinism type 1 KG + DL
44 hypouricemia, renal KG + DL
45 exocrine pancreatic insufficiency KG + DL
46 glycogen storage disease due to phosphoglycerate kinase 1 deficiency KG + DL
47 Waardenburg syndrome KG + DL
48 potassium deficiency disease KG + DL
49 glycogen storage disease due to muscle and heart glycogen synthase deficiency KG + DL
50 benign recurrent intrahepatic cholestasis KG + DL

(Showing top 50 of 53 predictions)

Disclaimer

These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.


← Back to Drug Search


Copyright © 2026 藥提醒科技有限公司 (yao.care). This report is for research purposes only and does not constitute medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.